DAPA & AbbVie – Women’s Health Sessions – Session 1 – Wednesday, June 23

We're sorry, but all tickets sales have ended because the event is expired.
  •  June 23, 2021
     6:00 pm - 7:00 pm


WEBINAR 1: Wednesday, June 23, 2021 – 6PM CT 

Endometriosis and Elagolix, indicated for moderate to severe endometriosis pain.

One of the most common gynecologic disorders in the U.S., and affecting  roughly 10% (190 million) of reproductive age women and girls worldwide, endometriosis is a highly estrogen-dependent, chronic, inflammatory disease characterized by the growth of endometrial tissue (similar to the lining of the uterus) outside the uterus, causing pain and/or infertility. ORILISSA (Elagolix)represents the first FDA-approved gonadotropin releasing hormone receptor antagonist in the market, and oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade.

This presentation will provide a brief overview of endometriosis disease state, and clinical trial data for Elagolix, indicated for moderate to severe endometriosis pain (FDA approved July 2018). https://www.rxabbvie.com/pdf/orilissa_pi.pdf

Women's Health_MSL_Maria Torres PhD